CTx, our Australian Partner consortium is one of the largest public/private partnerships of its type in the world.
CTx has been set up to benefit Australian researchers and their research institutes and is supported under the Australian Government’s Cooperative Research Centres Programme.
A dedicated cancer drug discovery and development company underpinned by AUD148M in public/private partnership funds, CTx works closely with leading Australian researchers and institutes to discover, protect and develop small molecule discoveries into pre-clinical drug candidates with commercial potential.
Their specific focus is small molecule cancer drugs or enabling therapeutics for single or co-therapy regimes - the next generation of global cancer therapies. CTx is well placed to do this, with internationally-respected expertise in molecular and cellular biology, drug discovery, pharmacology, structural biology and medicinal chemistry and with a global commercialisation partner (CRT) in cancer therapeutics to take the successful drug candidates forward through clinical development and to the market.
To find out more about CTx and its operations, please visit the website.
© Cancer Research Technology 2012